drugset / Trial / NCT00679965

Study of Different Doses of a Novel Treatment for Onychomycosis

NCT00679965

Phase 2 Completed 159 enrolled Pfizer
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the study is to determine the safety and efficacy of 2.5%, 5.0%, and 7.5% AN2690 Solutions compared to the vehicle alone in the treatment of distal, subungual onychomycosis of the great target toenail.

Timeline

Start
2006-02-28
Primary completion
2007-07-31
Completion
2007-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Tavaborole Small molecule 2.5 % Topical
Subject Tavaborole Small molecule 5 % Topical
Subject Tavaborole Small molecule 7.5 % Topical

Indications